Bi1015550薄膜包衣片
WebFeb 24, 2024 · BI 1015550 is an investigational, oral, phosphodiesterase 4B (PDE4B) inhibitor with combined antifibrotic and anti-inflammatory effects. BI 1015550 was studied as a monotherapy or in combination with background antifibrotic therapy to assess the effectiveness of slowing the rate of lung function decline in patients with IPF … WebDrug Registration and Acceptance is necessary for research and development of registered personnel, timely tracking drug review center review process, to check the competitive …
Bi1015550薄膜包衣片
Did you know?
WebJul 24, 2024 · This Study Tests How Healthy Men Tolerate Different Doses of BI1015550. The Study Also Tests How BI 1015550 is Taken up by the Body. Boehringer Ingelheim 23 April 2024. First Received: July 24, 2024 Last Updated: April 23, 2024. Phase: Phase 1 Start Date: August 10, 2024. WebDrug Registration and Acceptance is necessary for research and development of registered personnel, timely tracking drug review center review process, to check the competitive products and their own progress of the review and other information.
WebMay 17, 2024 · BI 1015550是一种新型的磷酸二酯酶4B（PDE4B）抑制剂，《新英格兰医学杂志》公布了其12周治疗的II期临床实验数据，研究结果极具前景 该项针对进展性肺纤 … WebMay 15, 2024 · New data suggests that the treatment of idiopathic pulmonary fibrosis (IPF) with BI 1015550- an oral preferential inhibitor of the phosphodiesterase 4 (PDE4) subtype- either alone or with an antifibrotic agent prevented a decrease in lung function. The phase 2 data was published today in the New England Journal of Medicine to coincide with the ...
WebBI 1015550是一种口服磷酸二酯酶4B（PDE4B）抑制剂，具有抗纤维化和抗炎作用。. BI 1015550有潜力同时解决肺纤维化（一种对肺功能产生负面影响的肺 ... WebBI 1015550 is an orally active inhibitor of PDE4B with an IC50 value of 7.2 nM. BI 1015550 has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD). For research use only. We do not sell to patients. BI 1015550 Chemical Structure CAS No. : 1423719-30-5
WebMay 20, 2024 · BI 1015550是一种口服磷酸二酯酶4B（PDE4B）抑制剂，具有抗纤维化和抗炎作用。 BI 1015550有潜力同时解决肺纤维化（一种对肺功能产生负面影响的肺组织不可逆疤痕）以及与进行性纤维化间质性肺疾病（ILD）相关的炎症。 今年2月，美国 FDA 授予了BI 1015550治疗IPF的突破性疗法认定（BTD）。 BTD是FDA的一个新药评审通道，旨在加 …
WebJun 10, 2024 · 方法： 今回の第II相、二重盲検、 プラセボ 対照 臨床試験 において、特発性肺線維症患者を対象に、経口投与のPDE4B亜型優先的阻害薬であるBI1015550の有効性と安全性を検証した。 対象患者はBI1015550 18mg/回を1日2回使用する群（BI群）と プラセボ 群（P群）に2:1の割合で無作為に割り付けられた。 主要評価項目は プロトコール … bluetooth radar crackedWebApr 11, 2024 · Inclusion criteria. Patients ≥40 years old at the time of signed informed consent. Signed and dated written informed consent in accordance with ICH-GCP and … bluetooth radar downloadWebOct 26, 2024 · FIBRONEER ™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, in idiopathic pulmonary … bluetooth radar gunWebMay 15, 2024 · In this placebo-controlled trial, treatment with BI 1015550, either alone or with background use of an antifibrotic agent, prevented a decrease in lung function in … bluetooth rackmount playerWebMar 24, 2024 · BI 1015550 III期临床试验FIBRONEER™包括两项随机、双盲、安慰剂对照试验，旨在评估创新药物磷酸二酯酶4B（PDE4B）选择性抑制剂BI1015550在特发性肺纤维 ... bluetooth radar marineWebJan 5, 2024 · BI 1015550....a new drug trial joblow Jan 4, 2024 • 5:47 PM Been a while since posting here. I was diagnosed with IPF some nine years ago. I was in the Fibrogen trial and subsequently continued receiving Fibrogen for a couple more years after the trial. bluetooth radarwarnerWebApr 20, 2024 · In summary, the unique preferential inhibition of PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic potential, suggest BI 1015550 to be a promising oral clinical candidate for the treatment of IPF and other fibro-proliferative diseases. Graphical Abstract Introduction bluetooth radar free